Ana Pilar Ramos Ttito

Dr. Ana Pilar Ramos Ttito

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
ATAna Pilar Ramos Ttito
Ana Pilar Ramos Ttito
SLSonja E. Leonhard
Sonja E. Leonhard
SHSusan K. Halstead
Susan K. Halstead
MCMireya A. Cuba
Mireya A. Cuba
CCCarlos C. Castañeda
Carlos C. Castañeda
CPCarlos A. Pardo-Villamizar
Carlos A. Pardo-Villamizar
Objective To identify the clinical phenotypes and infectious triggers in the 2019 Peruvian Guillain-Barré syndrome (GBS) outbreak. Methods We prospectively collected clinical and neurophysiologic data of patients with GBS admitted to a tertiary hospital in Lima, Peru, between May and August 2019. Molecular, immunologic, and microbiological methods were used to identify causative infectious agents. Sera from 41 controls were compared with cases for antibodies to Campylobacter jejuni and gangliosides. Genomic analysis was performed on 4 C jejuni isolates. Results The 49 included patients had a median age of 44 years (interquartile range [IQR] 30–54 years), and 28 (57%) were male. Thirty-two (65%) had symptoms of a preceding infection: 24 (49%) diarrhea and 13 (27%) upper respiratory tract infection. The median time between infectious to neurologic symptoms was 3 days (IQR 2–9 days). Eighty percent had a pure motor form of GBS, 21 (43%) had the axonal electrophysiologic subtype, and 18% the demyelinating subtype. Evidence of recent C jejuni infection was found in 28/43 (65%). No evidence of recent arbovirus infection was found. Twenty-three cases vs 11 controls (OR 3.3, confidence interval [CI] 95% 1.2–9.2, p < 0.01) had IgM and/or IgA antibodies against C jejuni. Anti-GM1:phosphatidylserine and/or anti-GT1a:GM1 heteromeric complex antibodies were strongly positive in cases (92.9% sensitivity and 68.3% specificity). Genomic analysis showed that the C jejuni strains were closely related and had the Asn51 polymorphism at cstII gene. Conclusions Our study indicates that the 2019 Peruvian GBS outbreak was associated with C jejuni infection and that the C jejuni strains linked to GBS circulate widely in different parts of the world.

7 March 2022 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
LLLiliana López
Liliana López
BVBraulio Valencia
Braulio Valencia
FAFiorela Alvarez
Fiorela Alvarez
ATAna Pilar Ramos Ttito
Ana Pilar Ramos Ttito
ACAlejandro Llanos Cuentas
Alejandro Llanos Cuentas
BAByron Arana
Byron Arana
Systemic pentavalent antimonials, mainly meglumine antimoniate, continue to be the first-choice drugs for treatment of cutaneous leishmaniasis (CL) despite their toxicity, difficulty of administration and high cost. In the search for therapeutic alternatives, combining two treatment interventions has emerged as a potential alternative to either reduce the use of antimonials with the associated toxicities, or to increase efficacy. Here, we report the results of a recently completed trial assessing the efficacy and safety of a combination of thermotherapy (TT) plus a short course of miltefosine (MLT) for the treatment of uncomplicated CL in Colombia and Peru. A multicenter, randomized, evaluator-blinded, phase II, controled clinical trial was conducted. Adult volunteers with a parasitologically confirmed diagnosis of uncomplicated CL were randomly allocated to receive either a single session of TT or a combination of TT plus a short course of MLT (3 weeks). Therapeutic response outcomes and safety were assessed. 130 subjects were included in the study, of whom 64 were randomly assigned to the TT arm and 66 to the TT + MLT arm. Cure at 3 months’ follow-up was achieved in 57.8% (n = 37) and 80.3% (n = 53) in the TT and TT + MLT groups, respectively, in the intention to treat analysis. The TT + MLT regimen was better that TT alone (p = 0.0055). The presence of vesicles at the site of heat application was the most common adverse event reported associated with the use of TT; while vomiting (31.8%) and elevation of liver enzymes (28.8%) were the most frequent adverse events reported associated with the use of MLT. The combination of TT plus a short course of MLT was shown to be significantly better than TT alone for the treatment of uncomplicated CL in the New World. Registered in clinicaltrials.gov NCT02687971. Cutaneous leishmaniasis is a disease caused by Leishmania parasites transmitted by sandflies. It is a complex and neglected disease. Generally, it manifests as ulcers, nodules, or other lesions, mainly on the face and extremities. An estimated 0.7–1 million new cases occur annually in around 88 countries in South and Central America, Africa, Europe, the Middle East, and Asia, with the appearance of new outbreaks in different regions of the world. For more than 70 years, pentavalent antimonials have been the first line treatment, despite their toxicity, varying efficacy and need of administration of painful injections for 20 days or more. There is limited availability of effective and safe treatment alternatives and the strength of scientific evidence on the efficacy and safety of the different schemes is variable, limiting the control of the disease from a therapeutic approach. Hence the need for effective, safe, low-cost treatment alternatives with non-invasive routes of administration. This article reports the results of a clinical trial aiming to evaluate a combined therapy with two therapeutic alternatives (miltefosine and thermotherapy) approved for the treatment of cutaneous leishmaniasis, comparing it with thermotherapy alone. In this study, the combined therapy was significantly better than the monotherapy in managing cutaneous leishmaniasis.

13 March 2023 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
ATAna Pilar Ramos Ttito
Ana Pilar Ramos Ttito
JBJorge G Burneo
Jorge G Burneo

8 September 2024 in Microbiology Research
Verified
Journal Article
Open access
PDF file
JRJesús Daniel Rojas
Jesús Daniel Rojas
MRMariana Ramos
Mariana Ramos
CCCristhopher Donats Cruz
Cristhopher Donats Cruz
KLKyle A. Long
Kyle A. Long
LVLogan Voegtly
Logan Voegtly
MGMax Grogl
Max Grogl
In 2018/2019, two large Guillain–Barré Syndrome (GBS) outbreaks took place in Peru. Here, we report a comprehensive analysis of biological samples from GBS patients from the 2019 outbreak. We applied metagenomic, microbiologic, and serological analyses to different biological samples collected from GBS patients. Further phenotypic and genomic characterization was conducted on Campylobacter jejuni isolates from GBS samples. Microbiologic and metagenomic analyses revealed several patients with multiple co-infections, yet no common infectious agents were found other than C. jejuni. Four C. jejuni isolates were isolated from rectal swabs. Twenty-one patients had detectable IgG serum antibodies related to C. jejuni, of whom seven had IgM antibodies. Genomic analyses showed that these four strains were clonal (ST2993) and contained the class A lipooligosaccharide biosynthesis locus. These results further support the idea that that C. jejuni is the etiological agent that triggered the GBS outbreak in Peru in 2019 and that the strains are not restricted to Peru, hence could be regarded as a broad public health concern. Furthermore, though we cannot delineate the role played by co-infections in GBS development, results obtained herein highlight metagenomic analysis as a potential new tool for depicting a yet unknown area of research in GBS.

3 July 2023 in Revista Médica Herediana
Verified
Journal Article
Open access
PDF file
ACAlejandro Llanos Cuentas
Alejandro Llanos Cuentas
JPJuan Pineda-Reyes
Juan Pineda-Reyes
FAFiorela Alvarez
Fiorela Alvarez
ATAna Pilar Ramos Ttito
Ana Pilar Ramos Ttito
BVBraulio M. Valencia
Braulio M. Valencia
Objetivos: Comparar la eficacia y toxicidad del antimoniato de meglumina (AM) y estibogluconato sódico (EGS) en el tratamiento de leishmaniasis cutánea (LC) en un hospital general. Material y métodos: Serie de casos comparativa de 193 pacientes con LC tratados en tres ensayos clínicos con AM (n=69) y EGS (n=124) durante 2001-2010. La administración de ambas drogas fue vía endovenosa lenta de 20 mg Sb5+/kg/día por 20 días consecutivos siguiendo las normativas de la OPS y OMS. La información clínica, toxicidad y eficacia fue obtenida de las historias clínicas almacenadas en el centro de investigación según la normativa local e internacional. Resultados: Las características demográficas fueron similares entre grupos, pero el tamaño y número de lesiones fueron mayores en el grupo AM. La eficacia del tratamiento con AM fue 76,0% versus 68,4% con EGS (p=0,340) y 55,1% versus 50,8% (p=0,570) en el análisis por protocolo y de intención de tratar, respectivamente. No se observaron efectos adversos inmediatos. Los síntomas más frecuentemente reportados fueron disgeusia (37,0%), mareos (32,0%), cefalea (36,0%), artralgias (31,0%) y linfangitis (21,0%). Los tres primeros síntomas, así como elevación de transaminasas, leucopenia, trombocitopenia y QTc prolongado fueron frecuentes en el grupo EGS, pero clínica y estadísticamente no significativos. El tratamiento fue suspendido definitivamente por toxicidad severa únicamente con EGS por emesis refractaria (2 participantes) y QTc prolongado con extrasístoles (1 participante). Conclusiones: La eficacia del tratamiento con AM y EGS fue comparable. La administración endovenosa de ambos no produjo efectosadversos inmediatos, aunque sí alteraciones clínicas y laboratoriales usuales.

8 October 2026 in Journal Of Clinical Neurophysiology
Verified
Journal Article
Closed access
UCUniversity of North Carolina
University of North Carolina
DODANIEL San Juan Orta
DANIEL San Juan Orta
CACarlos Alva-Diaz
Carlos Alva-Diaz
MBMaritza Beato
Maritza Beato
JBJuan Enrique Bender del Busto
Juan Enrique Bender del Busto
OEOn Behalf Of Consorcio Hispano de Monitoreo Electroencefalográfico
On Behalf Of Consorcio Hispano de Monitoreo Electroencefalográfico
Purpose: The American Clinical Neurophysiology Society (ACNS) Critical Care EEG Terminology provides standardized language for describing electroencephalographic (EEG) patterns in critically ill patients but has not been formally translated into Spanish. We aimed to develop a consensus-based Spanish translation of the ACNS Critical Care EEG Terminology using a multi-phase methodology involving physicians from Spanish-speaking countries. Methods: This qualitative study aimed to establish a standardized Spanish ACNS Critical Care EEG terminology through a three-phase process: Phase 1: Initial iterative translation by 14 Spanish-speaking physicians working in subgroups. Discrepancies were documented for further discussion. Phase 2: Focus groups with specialists practicing in Spanish-speaking countries, guided by qualitative research experts. Sessions explored terminology preferences, implementation challenges, and regional variations. Phase 3: Qualitative analysis and final consensus using a modified Delphi methodology. Ranked choice voting analysis to achieve ≥75% consensus was used and when needed, a two-option runoff determined the final selected term. Results: Forty-five physicians from all Spanish-speaking countries except Nicaragua participated in 10 focus groups to review 25 terms. Seven terms generated two possible Spanish translations, four generated three, five generated four, and nine generated five. A consensus-based Spanish terminology was established, prioritizing semantic fidelity to the ACNS terminology while also accounting for terms already in wide regional use. Examples of final consensus terms included: Generalized Periodic Discharges → Descargas Periódicas Generalizadas (98%, Round 1); Lateralized Rhythmic Delta Activity → Actividad Delta Rítmica Lateralizada (100%, round 1); and Sharp Wave → Onda Aguda (82%, round 1). The outdated term periodic lateralized epileptiform discharges remained widely used because of familiarity among intensivists. Conclusions: This effort provides the first structured Spanish adaptation of the ACNS Critical Care EEG terminology. The resulting lexicon reflects linguistic diversity across regions and supports consistent communication, training, research, and broader adoption of evidence-based continuous EEG practices.